QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

-SEC Filing

Core News & Articles

Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development...

Core News & Articles

Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.11) per share. This is a 99.46 percent increase over losses of $(20...

Core News & Articles

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southe...

Core News & Articles

Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharma...

Core News & Articles

Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $(8.04) ...

Core News & Articles

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to ...

Core News & Articles

Event to highlight the differentiated features of Traws oral small molecule product candidates:Tivoxavir Marboxil, a single dos...

Core News & Articles

TXM is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dos...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION